Extranodal NK/T-cell Lymphoma, Nasal Type Clinical Trial
Official title:
A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma
The purpose of this study is to prove the superiority of concurrent chemoradiation compared with radiotherapy alone in patients with low risk NK/T-cell lymphoma.
Radiotherapy alone is commonly used in NK/T-cell lymphoma without adverse risk including lymph node involvement, local invasion, B symptoms and high LDH level. Recently, methotrexate was prove to be a radiosensitizer in NK/T-cell lymphoma cells. Therefore, the investigators aim to verify the superiority and safety of weekly methotrexate in combination with radiotherapy in a randomized phase II study. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04509466 -
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04676789 -
Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL
|
Phase 2 | |
Active, not recruiting |
NCT01991158 -
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03363555 -
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04405375 -
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
|
Phase 2 | |
Recruiting |
NCT02742727 -
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02631239 -
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT01667302 -
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT04338282 -
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04414163 -
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
|
Phase 2 | |
Recruiting |
NCT05978141 -
A Registry for People With T-cell Lymphoma
|
||
Completed |
NCT02386813 -
International Extranodal NK/T-cell Lymphoma Project
|
N/A | |
Recruiting |
NCT01921790 -
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
|
Phase 2 | |
Completed |
NCT03493451 -
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
|
Phase 2 |